The European Medicines Agency (EMA) is launching an investigation into the safety of the Cervarix, Gardasil, Gardasil 9, and Silgard vaccines. (1)

ROCHESTER, NEW YORK, UNITED STATES OF AMERICA, August 9, 2015 /EINPresswire.com/ --

“Infected with the human papillomavirus (HPV)? The CBCD recommends taking Gene-Eden-VIR or Novirin.” - Greg Bennett, CBCD

European health regulators announced an investigation into the safety of all HPV vaccines after receiving many complaints regarding dangerous side effects. According to some of the families involved, “Previously healthy teenagers have suffered fits, extreme tiredness or even been left wheelchair-bound. Official figures show the HPV vaccination programme has drawn 8,228 reports of suspected side-effects since being launched in 2008, almost as much as all other routine jabs put together.” (2) In beginning its safety review, the European Medicines Agency (EMA) said in a statement that “The current review will look at available data with a focus on rare reports of two conditions: complex regional pain syndrome (CRPS, a chronic pain condition affecting the limbs) and postural orthostatic tachycardia syndrome (POTS, a condition where the heart rate increases abnormally after sitting or standing up, causing symptoms such as dizziness and fainting, as well as headache, chest pain and weakness). (3)

Additionally, some families reported that “Parents are not being given enough information about potential side-effects of the vaccine … girls who fall ill after vaccination are not being taken seriously by GPs (General Physicians) when parents suggest the illness could be vaccine-related. Jackie Fletcher, of pressure group Jabs, said: 'Previously fit and healthy young girls have developed seizures or viral fatigue, some have lost the ability to walk. And years on, some have still not recovered.'” (4)

The Center for the Biology of Chronic Disease (CBCD) points out that while many governments have approved the HPV vaccine, still there is a minority of experts urging caution. For example, Dr. Uzi Beller, chief professor of obstetrics/gynecology at Shaare Zedek Medical Center in Israel, urged the medical community to be cautious in regards to HPV vaccination. “I want to see fundamental studies proving efficacy, and they do not exist.” (See the Jerusalem Post, from September 21, 2013) (5)

The vaccines, Beller said, “were tested on mostly white women attending colleges and university - mostly from developed countries and healthy. The data were based on a relatively short term follow-up period. What is known does not yet justify widespread vaccination of healthy girls.” (5) In addition, Dr. Beller said that “there is no evidence that prophylactic (preventative) vaccination against HPV types 16 and 18 reduces the incidence of cervical cancer.” As the vaccine costs $100 to $360 for three doses in wealthy countries, it is completely out of the reach of developing countries, where an effective vaccine would be most urgently needed.” (5)

The Jerusalem Post report concluded that “pediatricians are important advocates for preventive medicine, but they may know little about HPV infection and cervical and other HPV-related cancers. Obstetricians / Gynecologists know about HPV and cervical cancer prevention, but they often know little about vaccines and immunization delivery.” (5)

Click to learn more about HPV symptoms.

“We believe doctors need facts. Many times, they’re recommending vaccination to their patients because that’s the party line of the National Health Service (NHS) at the moment.” - Greg Bennett, CBCD

A recent post marketing clinical study published in the peer reviewed, medical journal Pharmacology & Pharmacy, in a special edition on Advances in Antiviral Drugs on August 12, 2013 showed that the formula of Novirin and Gene-Eden-VIR reduced HPV symptoms and was safe and effective. (6)

The formula of Novirin and Gene-Eden-VIR was tested by Hanan Polansky and Edan Itzkovitz from the CBCD in two clinical studies that followed FDA guidelines. The studies showed that the Novirin and Gene-Eden-VIR formula is effective against the HPV and other viruses. The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy, the first, in a special edition on Advances in Antiviral Drugs. Study authors wrote that, “individuals infected with the HPV…reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR.” (6) The study authors also wrote that “we observed a statistically significant decrease in the severity, duration, and frequency of symptoms.” (6)

Both products can be ordered online on the Novirin and Gene-Eden-VIR websites, here:

http://www.gene-eden-vir.com

and

http://www.novirin.com

Novirin and Gene-Eden-VIR are natural antiviral dietary supplements. Their formula contains five natural ingredients: Selenium, Camellia Sinesis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses.

To date, Novirin and Gene-Eden-VIR are the only natural antiviral products on the market with published clinical studies that support their claims. Note: Novirin has the same formula as Gene-Eden-VIR. However, it contains higher quality and more expensive ingredients.

Doctors can view the papers on Gene-Eden-VIR here:
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101

http://www.scirp.org/journal/PaperInformation.aspx?PaperID=44234#.VIBA_NKUf90

Are there other treatments or remedies available against the HPV?

“There are no drugs approved against the HPV. Current treatments include procedures, such as cryotherapy, conization, and the Loop Electrosurgical Excision Procedure (LEEP). These procedures use liquid nitrogen, a surgical knife (scalpel), a carbon dioxide (CO2) laser, or electrical current to remove the abnormal growths caused by the HPV. These growths include cells that harbor the active virus (this is before the HPV has caused cancer). The procedures do not target cells with the latent virus. Since they do not remove the latent virus, these procedures only produce a temporary remission.” (6)

In light of this evidence, the CBCD recommends that HSV infected individuals take Gene-Eden-VIR or Novirin. These natural products do not prevent HPV infection, and they are not a cure for conditions caused by the virus. HPV establishes a life-long infection and there are no drugs or natural remedies that completely remove the virus from the body.

However, the formula of Gene-Eden-VIR and Novirin was shown to safely and effectively reduce HPV symptoms in two separate post-marketing clinical studies that followed FDA guidelines. Additionally, it was designed to help the immune system target the latent human papillomavirus.

All orders of these products are completely confidential, and no information is shared or sold to any third party. Privacy is assured.

Reference:

(1) European Medicines Agency - Human papillomavirus vaccines - "EMA to further clarify safety profile of human papillomavirus (HPV) vaccines" Published July 13, 2015

(2) Spencer, B "Safety probe into cervical cancer jab: Families win action over side-effects" Published July 13, 2015. DailyMail.co.uk
(3) Gever, J. "EMA to Probe HPV Vaccination Safety" Published July 13, 2015 - MedPage Today
(4) Macrae, F. "Tens of thousands of teenage girls believed to have fallen ill with debilitating illnesses after routine HPV cervical cancer jab." Last updated June 1, 2015. Mail Online
(5) Siegel-Itzkovich, J. "HPV: To vaccinate or not to vaccinate." Published September 21, 2013.http://www.jpost.com/Health-and-Science/HPV-To-vaccinate-or-not-to-vaccinate-326711
(6) Polansky H, Itzkovitz E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Pharmacology & Pharmacy, 2013, 4, 1-8

Greg Bennett
CBCD
585-250-9999
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.